• CD28 targeting
  • How it works
PEGS Boston – Advancing Bispecific Antibodies and Combination Therapy to the Clinic

PEGS Boston – Advancing Bispecific Antibodies and Combination Therapy to the Clinic

19th annual PEGS Boston - Nicolas Fischer -


Light Chain Bioscience is very pleased to have Nicolas Fischer, CEO, speaking at the Protein Engineering Summit in Boston on CD28 co-stimulatory bispecific antibody programs in the session entitled “Advancing Bispecific Antibodies and Combination Therapy to the Clinic


May 15-19, 2023

Boston MA, Hynes convention center & virtual

Back to News

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn